Cerner Corporation (CERN)
(Delayed Data from NSDQ)
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Avanos Medical's (AVNS) App to Support Pain Management Process
by Zacks Equity Research
Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.
Cerner (CERN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cerner (CERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cerner (CERN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cerner (CERN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains across four of its business units.
Cerner (CERN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 4.88% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect gains from strategic deals.
Cerner (CERN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner's (CERN) Latest Offering to Improve RCM Portfolio
by Zacks Equity Research
Cerner's (CERN) latest offering is likely to streamline and automate revenue cycle via interoperability and enhanced usability.
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges
by Urmimala Biswas
Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.
Why Cerner (CERN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.
Cerner (CERN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) second-quarter results benefit from gains across six of its business units.
Cerner (CERN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 5.26% and 1.30%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cerner (CERN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) second-quarter results are likely to reflect gains from strategic deals.
Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cerner (CERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.
PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Cerner (CERN) Extends Partnership to Accelerate Digital Health
by Zacks Equity Research
Cerner (CERN) expands its partnership with Baystate Health by launching a digital health platform to boost consumer-focused care.
Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus
by Trina Mukherjee
Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.
Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner